55
Participants
Start Date
October 26, 2015
Primary Completion Date
April 3, 2018
Study Completion Date
March 4, 2021
Avelumab (MSB0010718C)
Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
Axitinib (AG-013736)
Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
Laura & Isaac Perlmutter Cancer Center At NYU Langone, New York
NYU Langone Medical Center, New York
Georgetown University Medical Center, Washington D.C.
Cleveland Clinic Taussig Cancer Center, Cleveland
Cleveland Clinic, Cleveland
University of Utah, Huntsman Cancer Hospital, Salt Lake City
University of Utah, Huntsman Cancer Institute, Salt Lake City
Scottsdale Healthcare Hospitals d/b/a HonorHealth, Scottsdale
Brigham & Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Henry Joyce Cancer Clinic, Nashville
Niigata University Medical & Dental Hospital, Chuo-ku, Niigata
Kindai University Hospital, Sayama
Keio University Hospital, Shinjuku-ku
Mount Vernon Cancer Center, East and North Herts. NHS Trust, London
St Helier Hospital, Carshalton
St. Bartholomew's Hospital, London
The Royal Marsden NHS Foundation Trust, London
The Christie NHS Foundation Trust, Manchester
The Royal Marsden NHS Foundation Trust, Sutton
Lead Sponsor
Pfizer
INDUSTRY